Li M, et al. - Through 428 identified studies for cervical cancer patients, the researchers performed a systematic review and meta-analysis to assess the recurrence-free survival (RFS), overall survival (OS), grade III/IV hematologic toxicity and grade III/IV non-hematologic toxicity in chemoradiotherapy (CRT) vs radiotherapy (RT) groups. While grade III/IV non-hematologic toxicity was ambiguous for CRT and RT, the occurrence rate of grade III/IV hematologic toxicity was noted significantly higher in CRT. Hence, it was concluded that CRT could dramatically improve RFS and OS in comparison with RT for early-stage cervical cancer patients with intermediate-risk factors. Furthermore, CRT was noted to tolerate and accept treatment very well for early-stage cervical cancer, apart from the increase in grade III/IV hematologic toxicity.